Preventing diet-induced obesity in mice by adipose tissue transformation and angiogenesis using targeted nanoparticles

The incidence of obesity, which is recognized by the American Medical Association as a disease, has nearly doubled since 1980, and obesity-related comorbidities have become a major threat to human health. Given that adipose tissue expansion and transformation require active growth of new blood vascu...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 113; no. 20; pp. 5552 - 5557
Main Authors Xue, Yuan, Xu, Xiaoyang, Zhang, Xue-Qing, Farokhzad, Omid C., Langer, Robert
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 17.05.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The incidence of obesity, which is recognized by the American Medical Association as a disease, has nearly doubled since 1980, and obesity-related comorbidities have become a major threat to human health. Given that adipose tissue expansion and transformation require active growth of new blood vasculature, angiogenesis offers a potential target for the treatment of obesity-associated disorders. Here we construct two peptide-functionalized nanoparticle (NP) platforms to deliver either Peroxisome Proliferator-Activated Receptor gamma (PPARgamma) activator rosiglitazone (Rosi) or prostaglandin E2 analog (16,16-dimethyl PGE2) to adipose tissue vasculature. These NPs were engineered through self-assembly of a biodegradable triblock polymer composed of end-to-end linkages between poly(lactic-coglycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG) and an endothelial-targeted peptide. In this system, released Rosi promotes both transformation of white adipose tissue (WAT) into brown-like adipose tissue and angiogenesis, which facilitates the homing of targeted NPs to adipose angiogenic vessels, thereby amplifying their delivery. We show that i.v. administration of these NPs can target WAT vasculature, stimulate the angiogenesis that is required for the transformation of adipose tissue, and transform WAT into brown-like adipose tissue, by the up-regulation of angiogenesis and brown adipose tissue markers. In a diet-induced obese mouse model, these angiogenesis-targeted NPs have inhibited body weight gain and modulated several serological markers including cholesterol, triglyceride, and insulin, compared with the control group. These findings suggest that angiogenesis-targeting moieties with angiogenic stimulator-loaded NPs could be incorporated into effective therapeutic regimens for clinical treatment of obesity and other metabolic diseases.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
Reviewers: S.J., Korea Advanced Institute of Science and Technology; and L.Z., University of California, San Diego.
Contributed by Robert Langer, March 28, 2016 (sent for review January 12, 2016; reviewed by and Sangyong Jon and Liangfang Zhang)
1Y.X. and X.X. contributed equally to this work.
Author contributions: Y.X., X.X., X.-Q.Z., O.C.F., and R.L. designed research; Y.X., X.X., and X.-Q.Z. performed research; Y.X., X.X., X.-Q.Z., O.C.F., and R.L. analyzed data; and Y.X., X.X., X.-Q.Z., O.C.F., and R.L. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1603840113